BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Debt Repayment

Cash used to repay borrowings during the period.

BioAge Labs, Inc.NASDAQ: BIOA

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment grows in line with its trailing trend

Q1 FY2026 debt repayment of $1.5M (cash outflow) rose 0.0% year over year, in line with the +0.0% change in trailing-twelve-month debt repayment. Sequentially, it rose 0.0% from the prior quarter.

Context

  • Debt repayment amounted to 66.7% of revenue in FY2025.
  • Debt repayment increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +0.0% holds above the trailing-twelve-month pace of +0.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.5M+0.0% QoQ
Last fiscal yearDec 2025
-$6M+0.0% YoY
LTMMar 2026
-$6M+0.0% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year+0.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(6M) USD
Year-over-year change
+0.0%

Debt Repayment vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.0% is the 5th highest of 6, against a peer median of +156.7%.
  • Debt repayment amounts to 58.2% of revenue for BIOA, versus a peer median of 4.7%.
BIOA Competitors
Debt Repayment for BIOA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HUMAHumacyte, Inc.LTM Mar 2026$37.07M USD+44233.3%—1838.9%
CGCCanopy Growth CorporationLTM Mar 2026CA$13.52M CAD-93.9%—4.3%
BIOABioAge Labs, Inc.LTM Mar 2026$6M USD+0.0%—58.2%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$5.13M USD—-30.6%3.8%
ACBAurora Cannabis Inc.LTM Mar 2026CA$4.24M CAD+426.3%—1.4%
CABACabaletta Bio, Inc.LTM Mar 2026$3.72M USD+156.7%——
EDITEditas Medicine, Inc.LTM Mar 2026$2.87M USD——7.4%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.15M USD+93.3%-52.2%5.1%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding BIOA) —+156.7%-41.4%4.7%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Depreciation & Amortization129K162K167K213K
Deferred Income Tax0000
Stock-Based Compensation2.54M3.02M6.98M11.69M
Change in Working Capital795K6.71M11.18M(11.83M)
Accounts Receivables000(769K)
Inventory0000
Accounts Payables994K(393K)6K788K
Other Working Capital(199K)7.1M11.17M(11.85M)
Other Non-Cash Items77K16.6M1.27M(1.1M)
Operating Cash Flow(36.18M)(37.36M)(51.52M)(81.63M)
Capital Expenditures(103K)(166K)(366K)(719K)
Acquisitions (Net)0000
Purchases of Investments0(100K)0(154.75M)
Sales of Investments00060.25M
Other Investing Activities0000
Investing Cash Flow(103K)(266K)(366K)(95.22M)
Debt Repayment2.5M35M(6M)(6M)
Common Stock Issued44K0221.62M17.87M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(45K)(59K)(4.42M)(400K)
Financing Cash Flow2.5M34.94M381.2M11.47M
Effect of Forex Changes246K081K(87K)
Net Change in Cash(33.54M)(2.69M)329.39M(165.46M)
Free Cash Flow(36.28M)(37.53M)(51.89M)(82.35M)

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.